2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Multi-Arm Multi-Stage – a new approach to clinical trials
One of the most frustrating aspects of clinical trials is the long delays between studies. Dr Camille Carroll is leading a group of researchers exploring the use of multi-arm multi-stage clinical trials for Parkinson’s.
Fox Insight launches COVID-19 survey
Fox Insight, the online Parkinson’s clinical study, have launched their ‘COVID study’ designed to capture experiences from people with and without Parkinson’s disease. With little research being carried out on the impact of COVID-19 on the Parkinson’s community, Fox Insight, the online Parkinson’s clinical study,…
The STEADY-PD trial results
The results of the Phase lll STEADY-PD clinical trial have now been published.
A better delivery of Dopamine
People with Parkinson’s have a severe reduction in levels of a protein called dopamine in their brains. Lower levels of dopamine are associated with the motor symptoms of the condition (slowness and rigidity of movement). Doctors prescribe treatments that replace this lost dopamine as a…
3P: Parkinson Postdoc Program Seminars
Cure Parkinson’s, Van Andel Institute and World Parkinson Coalition Institute present: The 3P Parkinson Postdoc Program Seminars